Opendata, web and dolomites

oWBI

Osmotic Wearable Bolus Injector (oWBI) for viscous drug delivery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 oWBI project word cloud

Explore the words cloud of the oWBI project. It provides you a very rough idea of what is the project "oWBI" about.

osmotic    drugs    deals    companies    profit    performance    depending    attractive    moving    subcutaneous    doses    intravenous    pressure    components    viscosity    achievement    mechanical    170    disease    injectors    trend    optimal    dose    ing    cagr    successful    scj    administration    accumulated    formulations    eco    prefilled    region    competitor    segment    class    combination    coming    nature    customization    wbi    wbis    synthetic    establishing    self    aps    sc    larger    closer    ed    2025    unlike    2020    paired    licensing    convenient    75    bearing    lower    onto    biologically    commercialize    dominated    grow    assist    strategy    flexible    disposable    seeking    completion    electronic    2015    86    subcuject    9bn    market    company    significantly    medication    bolus    force    worn    patient    migrate    injection    body    multiple    predictable    97m    actively    profitability    business    pharmaceutical    medical    drug    wearable    device    paying    with    remarkably   

Project "oWBI" data sheet

The following table provides information about the project.

Coordinator
SUBCUJECT APS 

Organization address
address: NORDRE STRANDVEJ 119
city: HELLEBAEK
postcode: 3150
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://subcuject.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2018-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SUBCUJECT APS DK (HELLEBAEK) coordinator 50˙000.00

Map

 Project objective

With more drugs coming onto the market as combination products, i.e. drug products paired with delivery devices pharmaceutical companies are paying closer attention to integrated delivery systems. Due to: 1) the trend in the change in drug formulations, in order to migrate from intravenous to a more cost-effective and convenient subcutaneous (SC) drug administration; and 2) the trend in moving from synthetic derived drugs to biologically drugs that are more complex and have higher viscosity and therefore require delivery of larger doses; resulted in the need for a new class of injection devices - wearable bolus-injectors (WBIs). WBIs are prefilled, disposable devices that are worn on the body of a patient during the SC self-administration of a large dose of medication. The WBI market is estimated to grow in CAGR of 170% between 2015 – 2020 and achieve €6.9Bn by 2025, and pharmaceutical companies are actively seeking for reliable and cost-effective WBIs, providing optimal injection performance at an attractive unit cost and low cost of customization.

Subcuject ApS (SCJ) is a medical device company set to commercialize a new class of WBIs - Subcuject - that makes use of the simple, predictable and strong force of nature: osmotic pressure. Unlike the current WBIs, Subcuject is fully mechanical, bearing no electronic components, resulting in a more flexible, reliable and eco-friendly device at a remarkably lower cost than competitor’s (75 - 86% cost reduction).

SCJ business strategy is based on establishing multiple licensing deals (depending on the drug type, disease, region) with pharmaceutical companies. The Subcuject device is expected to significantly enhance SCJ’s profitability, with an expected accumulated profit of €97M, 5 years after project completion. Moreover, the successful achievement of the project objectives will assist SCJ to be a leading company in the WBI device segment in a market today dominated by U.S. companies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OWBI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OWBI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

WiNerve (2017)

Wireless Surgical Nerve Monitoring System

Read More  

HYBCOPTER (2016)

Hybrid multi copter with 6 times more flight time.

Read More  

Assist (2015)

Telocate ASSIST – Development and marketing of an acoustic solution for localization and navigation of people in buildings using the smartphone

Read More